4.5 Article

The Relationship of Brain Amyloid Load and APOE Status to Regional Cortical Thinning and Cognition in the ADNI Cohort

Journal

JOURNAL OF ALZHEIMERS DISEASE
Volume 59, Issue 4, Pages 1269-1282

Publisher

IOS PRESS
DOI: 10.3233/JAD-170286

Keywords

ADNI; Alzheimer's disease; amyloid; APOE; cortical thinning; memory; mild cognitive impairment

Categories

Funding

  1. National Science Foundation (NSF) under NSF grants [CNS-1532061, CNS-0959985, CNS-1551221, HRD- 0833093, IIP 1338922]
  2. Ware Foundation
  3. Florida Department of Health
  4. Ed and Ethel Moore Alzheimer's Disease Research Program
  5. 1Florida ADRC (Alzheimer's Disease Research Center) [1P50AG047266-01A1, R01 AG047649-01A1]
  6. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant) [U01 AG024904]
  7. DOD ADNI (Department of Defense award) [W81XWH-12-2-0012]
  8. National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering
  9. AbbVie
  10. Alzheimer's Association
  11. Alzheimer's Drug Discovery Foundation
  12. Araclon Biotech
  13. BioClinica, Inc.
  14. Biogen
  15. Bristol-Myers Squibb Company
  16. CereSpir, Inc.
  17. Cogstate
  18. Eisai Inc.
  19. Elan Pharmaceuticals, Inc.
  20. Eli Lilly and Company
  21. Eurolmmun
  22. F. Hoffmann-La Roche Ltd
  23. Genentech, Inc.
  24. Fujirebio
  25. GE Healthcare
  26. IXICO Ltd.
  27. Janssen Immunotherapy Research & Development, LLC.
  28. Johnson & Johnson Pharmaceutical Research & Development LLC.
  29. Lumosity
  30. Lundbeck
  31. Merck Co., Inc.
  32. Meso Scale Diagnostics, LLC.
  33. Neu-roRx Research
  34. Neurotrack Technologies
  35. Novartis Pharmaceuticals Corporation
  36. Pfizer Inc.
  37. Piramal Imaging
  38. Servier
  39. Takeda Pharmaceutical Company
  40. Transition Therapeutics
  41. Canadian Institutes Institute on of Health Research
  42. ADNI clinical sites in Canada
  43. Direct For Computer & Info Scie & Enginr
  44. Division Of Computer and Network Systems [1551221] Funding Source: National Science Foundation
  45. Direct For Computer & Info Scie & Enginr
  46. Division Of Computer and Network Systems [1532061] Funding Source: National Science Foundation

Ask authors/readers for more resources

Background: Both amyloid (A beta beta) load and APOE4 allele are associated with neurodegenerative changes in Alzheimer's disease (AD) prone regions and with risk for cognitive impairment. Objective: To evaluate the unique and independent contribution of APOE4 allele status (E4+\E4-), A beta status (Amy+\Amy-), and combined APOE4 and A beta status on regional cortical thickness (CoTh) and cognition among participants diagnosed as cognitively normal (CN, n = 251), early mild cognitive impairment (EMCI, n = 207), late mild cognitive impairment (LMCI, n = 196), and mild AD (n = 162) from the ADNI. Methods: A series of two-way ANCOVAs with post-hoc Tukey HSD tests, controlling independently for A beta and APOE4 status and age were examined. Results: Among LMCI and AD participants, cortical thinning was widespread in association with Amy+ status, whereas in association with E4+ status only in the inferior temporal and medial orbito-frontal regions. Among CN and EMCI participants, E4+ status, but not Amy+ status, was independently associated with increased CoTh, especially in limbic regions [e.g., in the entorhinal cortex, CoTh was 0.123 mm greater (p = 0.002) among E4+ than E4- participants]. Among CN and EMCI, both E4+ and Amy+ status were independently associated with cognitive impairment, which was greatest among those with combined E4+ and Amy+ status. Conclusion: Decreased CoTh is independently associated with Amy+ status in many brain regions, but with E4+ status in very restricted number of brain regions. Among CN and EMCI participants, E4+ status is associated with increased CoTh, in medial and inferior temporal regions, although cognitive impairment at this state is independently associated with Amy+ and E4+ status. These findings imply a unique pathophysiological mechanism for E4+ status in AD and its progression.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available